
05/28/2025
... "The promise — but at what price?
No one can deny the dramatic weight loss some users experience. Social media feeds are full of it. For individuals with intractable obesity and associated complications, these injections may indeed represent a lifeline. But the public is being sold a simplified story — one of effortless slimming without the caveats.
Here’s what’s often left out, even from the MHRA advisory to health professionals:
Many users regain the weight within a year of stopping the drug, according to multiple studies, including a recent systematic review and meta-analysis published in Obesity Review.
Muscle loss accounts for a stunning 15-40% of the total weight lost, raising the indirect risk of frailty, immune dysfunction, bone health issues, and long-term metabolic instability.
Emerging data suggest nutrient deficiencies, mental health changes including increased risk of depression, anxiety and suicidal behavior, and potential thyroid cancer " ...
GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have rocketed from niche diabetes treatments to global “miracle” blockbuster drugs. Are we witnessing another pharma-fuelled bubble that downplays real risks, oversells benefits and ushers in lifelong medicalization for millions unde...